The company announced its estimated book value per common share of $18.06 as of February 28. This estimate includes the effect of the previously announced monthly dividend of 10c per common share, payable on March 25 to holders of record on February 26, with an ex-dividend date of February 25.

Adaptive Biotechnologies (ADPT) announced that the U.S. FDA issued an Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft (MSFT).

In an interview on CNBC's Mad Money, Todd McKinnon said Okta's (OKTA) combination with Auth0 gives customers great choice and flexibility. "It's not a small company, it's scaling," he said. "If you look at the SolarWinds (SWI) incident, it's clear that everything in the office must be secure," he added.

This is the 3rd consecutive decrease in holdings and the lowest level since May 1st, 2020.

In a regulatory filing, First Solar director George A. Hambro disclosed the sale of 10,000 common shares of the company on March 3 at a price of $80.67 per share.

CytoDyn reported the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. The trial's data has been reported to the U.S. Food and Drug Administration, the U.K.'s Medicines & Healthcare product Regulatory Agency and Health Canada, and the company is in discussions with each to determine the best path forward for approval of leronlimab for treatment of COVID-19 in critically ill population. A manuscript of the trial's data is being prepared and will be submitted for publication in one or more major medical journals. Scott A. Kelly, M.D., Chairman and Chief Medical Officer, noted, "We believe this further supports CCR5 as a therapeutic target for immunomodulation and the importance of the disruption of the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade of pro-inflammatory leukocytes and reversal of the cytokine storm in critical COVID-19 patients."

In a regulatory filing, Freeport McMoRan director Gerald J. Ford disclosed the sale of 300,000 common shares of the company on March 4 at a price of $33.2359 per share.

Luokung Technology announced that the company received a notice from Nasdaq informing the Company that as a result of the company being placed by the U.S. Department of Defense list of "Communist Chinese Military Companies" operating directly or indirectly in the United States, which are subject to certain restrictions under Executive Order 13959, that trading of the company's ordinary shares will be suspended at the opening of business on March 15, 2021. Nasdaq will file a Form 25-NSE with the SEC, which will remove the company's securities from listing and registration on The Nasdaq Stock Market. The company plans to appeal the Nasdaq Staff's determination to a Hearings Panel.

AT&T said: "Today's civil suit filed by the Securities and Exchange Commission targeting three AT&T mid-level investor relations employees for conversations they had with analysts five years ago represents a significant departure from the SEC's own long-standing Regulation FD enforcement policy and is inconsistent with the testimony of all who participated in these conversations. Tellingly, after spending four years investigating this matter, the SEC does not cite a single witness involved in any of these analyst calls who believes that material nonpublic information was conveyed to them. The information discussed during these March and April 2016 conversations concerned the widely reported, industry-wide phase-out of subsidy programs for new smartphone purchases and the impact of this trend on smartphone upgrade rates and equipment revenue. Not surprisingly, without device subsidies, customers upgraded their smartphones less frequently, leading to a reduction in equipment revenue. Not only did AT&T publicly disclose this trend on multiple occasions before the analyst calls in question, but AT&T also made clear that the declining phone sales had no material impact on its earnings. Analysts and the news media frequently wrote about this trend and investors understood that AT&T's core business was selling connectivity (i.e., wireless service plans), not devices, and that smartphone sales were immaterial to the company's earnings. The evidence could not be clearer - and the lack of any market reaction to AT&T's first quarter 2016 results confirms - there was no disclosure of material nonpublic information and no violation of Regulation FD. The SEC's pursuit of this matter will not protect investors and instead will only serve to chill productive communications between companies and analysts, something the SEC was worried about when it adopted Regulation FD some 20 years ago. Unfortunately, this case will only create a climate of uncertainty among public companies and the analysts who cover them. AT&T maintains the highest standards of ethics and compliance and we look forward to having our "day in court" to demonstrate conclusively that our investor relations employees complied with Regulation FD, and that the allegations in the SEC's complaints are meritless."

Walmart (WMT) announced that its Board of Directors has appointed Randall Stephenson, former Chairman and CEO of AT&T (T), as a new member of the company's board, effective March 3. Stephenson became the 12th member of the board.